Seres Therapeutics announces further constructive feedback from FDA on SER-155

Seres Therapeutics (MCRB) announced receipt of additional constructive feedback from the U.S. Food and Drug Administration, FDA, on the Phase 2 study protocol for the Company’s lead program, SER-155, for the prevention of bloodstream infections, BSIs, in adults undergoing allogeneic hematopoietic stem cell transplant. The feedback is expected to support Seres’ finalization of the protocol. The Company continues to engage with multiple parties intending to secure capital and other resources to support advancement of the Phase 2 study of SER-155, which has received Breakthrough Therapy designation, as well as further development of additional live biotherapeutic candidates. The Company also announced the implementation of actions to reduce operating costs, including a reduction in the workforce. As a result of the anticipated cost savings arising from these initiatives and current operating plans, the Company expects to extend its cash runway well into the second quarter of 2026.